Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same author

Robotic-assisted thoracoscopic surgery lobectomy versus open or video-assisted thoracoscopic surgery lobectomy for early-stage non-small cell lung cancer.

The Cochrane database of systematic reviews·2025
Same author

Conservative interventions for managing exercise-related musculoskeletal groin pain.

The Cochrane database of systematic reviews·2025
Same author

ChatGPT: immutable insertion in health research and researchers' lives.

Einstein (Sao Paulo, Brazil)·2024
Same author

Evidence for calcium supplementation in pregnancy: More than pre-eclampsia.

BJOG : an international journal of obstetrics and gynaecology·2024
Same author

Halofuginone for non-hospitalized adult patients with COVID-19 a multicenter, randomized placebo-controlled phase 2 trial. The HALOS trial.

PloS one·2024

Related Experiment Video

Updated: May 10, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Beta-blockers for preventing stroke recurrence.

Luiz Gustavo De Lima1, Bernardo G O Soares, Humberto Saconato

  • 1Brazilian Cochrane Centre, Universidade Federal de São Paulo, São Paulo, Brazil.

The Cochrane Database of Systematic Reviews
|June 4, 2013
PubMed
Summary
This summary is machine-generated.

Beta-blockers do not currently show evidence for preventing stroke recurrence or reducing vascular events in patients with a history of stroke or TIA. Further research with larger sample sizes is required to confirm these findings.

Related Experiment Videos

Last Updated: May 10, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Stroke impacts 15 million individuals globally each year, emphasizing the critical need for effective secondary prevention strategies.
  • Recurrence rates for stroke are high, necessitating ongoing research into interventions beyond acute treatment.
  • Beta-blockers are being investigated for their potential role in stroke secondary prevention due to their known effects beyond blood pressure reduction.

Purpose of the Study:

  • To assess the efficacy of beta-blockers in preventing stroke recurrence and reducing mortality and major vascular events in individuals with a prior stroke or TIA.
  • To evaluate the safety profile of beta-blockers, with a specific focus on their potential to induce diabetes mellitus.

Main Methods:

  • A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted.
  • Searches were performed across multiple databases including Cochrane, MEDLINE, and EMBASE up to December 2011.
  • Two RCTs involving 2193 participants comparing beta-blockers (atenolol) to placebo were included.

Main Results:

  • No statistically significant differences were observed in the risk of fatal or non-fatal stroke between the beta-blocker and placebo groups (RR 0.94, 95% CI 0.75 to 1.17).
  • Analysis of other outcomes, including all-cause mortality, cardiac death, non-fatal myocardial infarction, and major vascular events, revealed no significant differences between the treatment groups.
  • The safety data regarding the development of diabetes mellitus was not explicitly detailed in the main results but was part of the study's objective.

Conclusions:

  • Current evidence does not support the routine use of beta-blockers for secondary prevention following stroke or TIA.
  • Larger-scale studies with increased participant numbers are necessary to definitively establish the role, if any, of beta-blockers in stroke secondary prevention.
  • The findings suggest that other therapeutic strategies should be prioritized for secondary stroke prevention at this time.